title: Adjusted dose lenalidomide is safe and effective in patients with deletion (5q) myelodysplastic syndrome and severe renal impairment.
authors.forename: Stefan
authors.initials: S
authors.lastname: Knop
authors.forename: Hermann
authors.initials: H
authors.lastname: Einsele
authors.forename: Ralf
authors.initials: R
authors.lastname: Bargou
authors.forename: Denise
authors.initials: D
authors.lastname: Cosgrove
authors.forename: Alan
authors.initials: A
authors.lastname: List
mesh_terms: D000369:Aged, 80 and over; D002872:Chromosome Deletion; D002895:Chromosomes, Human, Pair 5; D005260:Female; D006801:Humans; D007674:Kidney Diseases / Q000209:etiology; D000077269:Lenalidomide; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000150:complications / Q000188:drug therapy* / Q000235:genetics*; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D013792:Thalidomide; D000077269:Lenalidomide